Vimedimex, Cermed GmbH sign cooperation agreement on peptide receptor radiotherapy application

This is considered the golden key to open the door, connecting Vietnam's health care system with the most advanced medical science in the world, contributing to improving the quality of life of Vietnamese people, moving closer and closer to the traditional prosperous economies of Europe.

Wealth is not only financial abundance, but also a healthy body, a clear mind and belief in goodwill, along with a big enough aspiration and a high enough passion, which are the driving forces contributing to building Vietnam into one of the prosperous and thriving powers with a happy life and a guaranteed quality of life for its people.

From a macro perspective, with a renewed vision and system management, Vimedimex Pharmaceutical Joint Stock Company devotes its intelligence, enthusiasm, and dedication to its expertise. With more than 40 years of experience as a pioneer in the pharmaceutical and medical fields of the country, Vimedimex is deeply aware of the importance of applying modern science and technology to medicine, as well as the core role of expanding strategic cooperation and has been implemented with leading pharmaceutical and medical corporations of countries with nuclear medicine (NMP), specializing in applying the radiation properties of radioactive isotopes or radioactive pharmaceuticals to research and evaluate two processes, pathophysiology and metabolism of the body, for the purpose of diagnosis and treatment.

The clinical application effectiveness of Traditional Medicine has contributed significantly to the application of advanced and modern science , improving the quality of diagnosis and treatment of patients, especially in some specialties such as cancer, cardiovascular, urology and endocrinology... These are important partners, with many significant contributions, remarkable effectiveness, in the spirit of dual responsibility, for both national interests and global responsibilities.

Signing ceremony.

Firstly, with the increasing development of radiopharmaceuticals suitable for theranostics diagnostic and therapeutic applications, the use of new radiopharmaceuticals has become widespread in the world and is being promoted for clinical application in Vietnam.

Therefore, Vimedimex, Cermed GmbH together with RadioVaxx GmbH, Wiesbaden signed a joint venture cooperation agreement with Eczacibasi Monrol (Eczacıbaşı-Monrol) of Turkey with the goal of producing and preparing: (1) Radiopharmaceuticals for the treatment of Pepti receptors and prostate-specific membrane antigen PSMA combined with β-emitting radionuclides (Lu-177, Y-90) or α-emitting radionuclides (Ac-225, Bi-213) in the treatment of neuroendocrine tumors with 177Lu-Dotatate and the treatment of metastatic prostate cancer; (2) Ge68/Ga68 predictive imaging radiopharmaceutical is a radioactive isotope with many potential new applications, especially in radioactive labeling, for diagnostic imaging to determine disease stage, monitor post-treatment response of neuroendocrine cancers, prostate cancer, etc.

(1) Neuroendocrine cancer and prostate cancer are very dangerous cancers for humans and are extremely complicated to treat. They can develop rapidly, are difficult to completely erase, and easily metastasize to many organs and areas of the body compared to other cancers. Neuroendocrine tumors are quite rare but have a high mortality rate due to late detection and limited treatment effectiveness.

(2) According to WHO statistics, prostate cancer ranks fourth among common cancers with nearly 1.3 million new cases and ranks eighth in mortality among cancers. Therefore, the radioactive isotope Ge68/Ga68 is indicated for use in positron emission tomography (PET), helping to identify positive lesions for prostate-specific membrane antigen (PSMA) in cancer patients.

The structure of the Ge68/Ga68 radiopharmaceutical is remarkable simple, consisting of a gallium-68 ion linked to a prostate-specific membrane antigen (PSMA) inhibitor ligand. The PSMA target ligand was first studied in combination with the technetium-99m radionuclide and modified to the corresponding gallium-68 derivative, which is now proven to be very effective in the diagnosis and radiosensitization of neuroendocrine and prostate tumors, thereby improving the chances of cure or long-term disease control for patients.

With the strategic cooperation of Vimedimex, Cermed GmbH with RadioVaxx GmbH, Wiesbaden and Eczacibasi Monrol, patients in Vietnam will soon enjoy the most advanced nuclear medicine achievements in the world today, directly produced, prepared and applied for treatment in Vietnam.

Second: In the new era of medical development, criteria to ensure drug efficacy and patient safety are of primary concern. A balanced assessment of the cost-benefit ratio of high-value therapies is essential. As society develops, biomarkers are increasingly emerging, for predictive molecular modeling and patient stratification, driven by the realization that genomic information facilitates understanding of the genetic basis of disease.

And today, it is an honor and pride that Vimedimex, Cermed GmbH officially cooperates comprehensively with RadioVaxx GmbH, Wiesbaden, run by Prof. Richard Baum, a great scientist, an outstanding and world-famous expert in the field of nuclear medicine to establish the first "Nuclear Molecular Radiotherapy Center" in Vietnam, with a scale of 10 to 12 beds treated with Peptide Receptor Radiotherapy (PRRT) a molecular-related therapy (Radioisotope Therapy) used to specifically treat cancers, carcinoid tumors, pancreatic adenocarcinoma, small cell lung cancer, melanoma (a rare tumor that forms in the adrenal gland), gastro-entero-pancreatic tumors (stomach, intestines and pancreas) neuroendocrine tumors.

This is a targeted therapy method, by linking a small peptide molecule with a radionuclide (usually β or α emitting) to create a special radiopharmaceutical radiopeptide to deliver precise doses of therapeutic radiation, to the target tumor cells and minimize damage to healthy cells.

Working with Nuclear Medicine and Oncology Center - Bach Mai Hospital.

In peptide receptor radionuclide therapy (PRRT), octreotide is combined with therapeutic doses of the radionuclides yttrium-90 (Y-90) and lutetium 177 (Lu-177), which are the most commonly used radionuclides. Lutetium Lu 177 dotatate is indicated for the treatment of somatostatin receptor-positive gastric neuroendocrine tumors (GEP-NETs), including visceral, midgut, and hindgut neuroendocrine tumors in adults and was approved by the FDA as Lutathera in January 2018 for intravenous administration. Lutetium Lu 177 dotatate showed higher radioactivity uptake in tumors and better residence time [A31696].

It can be said that this is a comprehensive demonstration, demonstrating the business orientation of Vimedimex and Cermed GmbH, which always puts the interests of patients at the top of their concerns. Through this cooperation, it will bring miracles, turning dreams that were once impossible, for many patients, into reality, in the not too distant future. When there is no need to cross the border, no need to pay huge amounts of money to distant centers and hospitals, but right in the beloved S-shaped land, people who are working hard day and night, fighting against incurable diseases, will have the opportunity to enjoy quality services and be treated with modern machinery systems, the most advanced science and technology in the world.

The community-oriented spirit of Vimedimex and Cermed GmbH demonstrates the passion and realization of providing access and treatment in a fair manner, regardless of rich or poor in today's society.

Third: BioNTech supports Cermed GmbH and Vimedimex to appoint IQ Vietnam Research Consulting Joint Stock Company (a member company of Vimedimex), managed by Associate Professor, Dr. Nguyen Viet Nhung, former Director of the Central Lung Hospital, holds the position of Chairman of the Board of Members and Director of the Company to direct and operate professional support in clinical research at medical examination and treatment facilities in Vietnam for cancer drugs.

Supervise, provide legal advice, organize conferences, seminars, training on clinical research skills and support and capacity building for parties involved in the field of clinical research in Vietnam. Because clinical research is conducted on people, patients or healthy volunteers, with the aim of developing a new treatment method or drug, determine the cause of the disease, determine disease trends, assess the relationship between disease and gene mutations.

In fact, clinical research is a branch of healthcare science that determines the safety and effectiveness of drugs, devices, diagnostic products, and treatment regimens for human patients. They may be used to prevent, treat, diagnose, or alleviate the symptoms of disease.

Clinical research is not only an activity that demonstrates deep expertise in experimental science, but also a mandatory requirement and a demonstration of humanity and human rights at the most practical and valuable level. This is also the noble mission that any individual or organization operates honestly in the field of medicine and pharmacy pursues and continuously.

The opening ceremony for comprehensive strategic cooperation activities between the Parties is the visit and working session of Professor Richard Baum with Vimedimex from February 4-6, 2023 in Hanoi. Professor Richard Baum is known by the scientific community worldwide as an outstanding and globally renowned expert in the field of nuclear medicine.

Professor Richard P. Baum. President of the International Academy of Precision Oncology (ICPO), member of the Council of ICPO, chairman of the ICPO Scientific Committee.

Professor Richard Baum has spent many years working as a leader in the Committees on Nuclear Medicine and Molecular Radioactivity, working closely with the heads of the IAEA.

During a special working trip in the early days of spring in Hanoi, Professor Richard Baum said: “This strategic cooperation agreement is not only a simple economic cooperation between multinational corporations developing in the field of nuclear medicine, but also a profound combination of scientific research and practical application of technology - a model that has been successful and sustainable in the world for many years.

With the direct participation of leading scientists in nuclear medicine and cancer treatment applications, the radioactive therapeutic and imaging drugs were born. This is the result of serious and comprehensive research, fully meeting the conditions, requirements, and strict inspections, integrating human knowledge and dedication with the ability to serve and treat with the world's leading quality, for cancer patients in Vietnam. This achievement is a gift crystallized from the love of humanity, which I personally, along with my colleagues, wholeheartedly dedicated to the Vietnamese people.

In the warm atmosphere of early spring days, Vimedimex and Cermed GmbH, through a historic strategic cooperation, between pharmaceutical corporations with a foundation of knowledge, modern technology and extensive experience in the field of nuclear medicine.

And perhaps, a journey of a thousand miles begins with a single step, that is the path of Vimedimex and Cermed GmbH illuminated by the intellectual light of Professor Richard Baum, of scientists around the world, bringing comprehensive wealth in physical health, peace of mind, prosperity in resources, to give and serve the people of Vietnam with sweet flavors of love, smiles and kind hearts./

Pv

Source: https://www.congluan.vn/vimedimex-cermed-gmbh-ky-ket-hop-tac-ung-dung-tri-lieu-phong-xa-thu-the-peptide-post234074.html